Glycaemic Control in People with Diabetes Starting Treatment with Fast-Acting Insulin Aspart: a US Database Study.
Wendy LaneMads FaurbyLise Lotte N HusemoenDmitriy L MarkovichNaveen RathorChristophe E M De BlockPublished in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2021)
US IBM® Explorys® data demonstrated a clinically relevant reduction in HbA1c 6 months after initiating faster aspart treatment for individuals with T2D, but not T1D overall, although patients with baseline HbA1c > 8.5% had significant HbA1c reductions regardless of diabetes type.